FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127106192> ?p ?o ?g. }

• W2127106192 endingPage "6176" @default.
• W2127106192 startingPage "6170" @default.
• W2127106192 abstract "The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is currently spreading among humans, making development of effective MERS vaccines a high priority. A defined receptor-binding domain (RBD) in MERS-CoV spike protein can potentially serve as a subunit vaccine candidate against MERS-CoV infections. To identify an ideal vaccine candidate, we have constructed five different versions of RBD fragments, S350-588-Fc, S358-588-Fc, S367-588-Fc, S367-606-Fc, and S377-588-Fc (their names indicate their residue range in the spike protein and their C-terminal Fc tag), and further investigated their receptor binding affinity, antigenicity, immunogenicity, and neutralizing potential. The results showed that S377-588-Fc is among the RBD fragments that demonstrated the highest DPP4-binding affinity and induced the highest-titer IgG antibodies in mice. In addition, S377-588-Fc elicited higher-titer neutralizing antibodies than all the other RBD fragments in mice, and also induced high-titer neutralizing antibodies in immunized rabbits. Structural analysis suggests that S377-588-Fc contains the stably folded RBD structure, the full receptor-binding site, and major neutralizing epitopes, such that additional structures to this fragment introduce non-neutralizing epitopes and may also alter the tertiary structure of the RBD. Taken together, our data suggest that the RBD fragment encompassing spike residues 377-588 is a critical neutralizing receptor-binding fragment and an ideal candidate for development of effective MERS vaccines, and that adding non-neutralizing structures to this RBD fragment diminishes its neutralizing potential. Therefore, in viral vaccine design, it is important to identify the most stable and neutralizing viral RBD fragment, while eliminating unnecessary and non-neutralizing structures, as a means of immunofocusing." @default.
• W2127106192 created "2016-06-24" @default.
• W2127106192 creator A5008068714 @default.
• W2127106192 creator A5023492006 @default.
• W2127106192 creator A5047727079 @default.
• W2127106192 creator A5047916176 @default.
• W2127106192 creator A5050951280 @default.
• W2127106192 creator A5051968927 @default.
• W2127106192 creator A5065582452 @default.
• W2127106192 creator A5069302796 @default.
• W2127106192 creator A5081394669 @default.
• W2127106192 creator A5081759253 @default.
• W2127106192 date "2014-10-01" @default.
• W2127106192 modified "2023-10-14" @default.
• W2127106192 title "Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design" @default.
• W2127106192 cites W15133725 @default.
• W2127106192 cites W1789264759 @default.
• W2127106192 cites W1974831307 @default.
• W2127106192 cites W1982533785 @default.
• W2127106192 cites W1992055074 @default.
• W2127106192 cites W1994482345 @default.
• W2127106192 cites W1998952429 @default.
• W2127106192 cites W2012505332 @default.
• W2127106192 cites W2013090907 @default.
• W2127106192 cites W2013852459 @default.
• W2127106192 cites W2016268672 @default.
• W2127106192 cites W2016428878 @default.
• W2127106192 cites W2016862068 @default.
• W2127106192 cites W2017191121 @default.
• W2127106192 cites W2021241053 @default.
• W2127106192 cites W2022439931 @default.
• W2127106192 cites W2029293367 @default.
• W2127106192 cites W2031436792 @default.
• W2127106192 cites W2033566457 @default.
• W2127106192 cites W2046071548 @default.
• W2127106192 cites W2049845957 @default.
• W2127106192 cites W2049975503 @default.
• W2127106192 cites W2054609914 @default.
• W2127106192 cites W2057172638 @default.
• W2127106192 cites W2078121682 @default.
• W2127106192 cites W2081861008 @default.
• W2127106192 cites W2083547697 @default.
• W2127106192 cites W2100790445 @default.
• W2127106192 cites W2103807321 @default.
• W2127106192 cites W2105558257 @default.
• W2127106192 cites W2105626573 @default.
• W2127106192 cites W2106921881 @default.
• W2127106192 cites W2108732610 @default.
• W2127106192 cites W2109115694 @default.
• W2127106192 cites W2119111857 @default.
• W2127106192 cites W2119248683 @default.
• W2127106192 cites W2120967846 @default.
• W2127106192 cites W2126080553 @default.
• W2127106192 cites W2131005359 @default.
• W2127106192 cites W2131153572 @default.
• W2127106192 cites W2132056320 @default.
• W2127106192 cites W2134781640 @default.
• W2127106192 cites W2141877163 @default.
• W2127106192 cites W2149508011 @default.
• W2127106192 cites W2151539653 @default.
• W2127106192 cites W2158084342 @default.
• W2127106192 cites W2160011624 @default.
• W2127106192 cites W2161588249 @default.
• W2127106192 cites W2161687688 @default.
• W2127106192 cites W2166867592 @default.
• W2127106192 cites W2167775515 @default.
• W2127106192 cites W2169462787 @default.
• W2127106192 cites W2170239105 @default.
• W2127106192 cites W4239796168 @default.
• W2127106192 doi "https://doi.org/10.1016/j.vaccine.2014.08.086" @default.
• W2127106192 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4194190" @default.
• W2127106192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25240756" @default.
• W2127106192 hasPublicationYear "2014" @default.
• W2127106192 type Work @default.
• W2127106192 sameAs 2127106192 @default.
• W2127106192 citedByCount "118" @default.
• W2127106192 countsByYear W21271061922015 @default.
• W2127106192 countsByYear W21271061922016 @default.
• W2127106192 countsByYear W21271061922017 @default.
• W2127106192 countsByYear W21271061922018 @default.
• W2127106192 countsByYear W21271061922019 @default.
• W2127106192 countsByYear W21271061922020 @default.
• W2127106192 countsByYear W21271061922021 @default.
• W2127106192 countsByYear W21271061922022 @default.
• W2127106192 countsByYear W21271061922023 @default.
• W2127106192 crossrefType "journal-article" @default.
• W2127106192 hasAuthorship W2127106192A5008068714 @default.
• W2127106192 hasAuthorship W2127106192A5023492006 @default.
• W2127106192 hasAuthorship W2127106192A5047727079 @default.
• W2127106192 hasAuthorship W2127106192A5047916176 @default.
• W2127106192 hasAuthorship W2127106192A5050951280 @default.
• W2127106192 hasAuthorship W2127106192A5051968927 @default.
• W2127106192 hasAuthorship W2127106192A5065582452 @default.
• W2127106192 hasAuthorship W2127106192A5069302796 @default.
• W2127106192 hasAuthorship W2127106192A5081394669 @default.
• W2127106192 hasAuthorship W2127106192A5081759253 @default.
• W2127106192 hasBestOaLocation W21271061921 @default.
• W2127106192 hasConcept C159047783 @default.

• next